Abstract:SUMOylation, one of post-translational modifications, is covalently modified on lysine residues of a target protein through an enzymatic cascade reaction similar to protein ubiquitination. Along with identification of many SUMOylated proteins, protein SUMOylation has been proven to regulate multiple biologic activities including transcription, cell cycle, DNA repair, and innate immunity. The dysregulation of protein SUMOylation and deSUMOylation modification is linked with carcinogenesis and tumor progression. The SUMOylation-associated enzymes are usually elevated in various cancers, which function as cancer biomarkers to relate to poor outcomes for patients. Considering the significance of protein SUMOylation in regulating diverse biologic functions in cancer progression, numerous small-molecule inhibitors targeting protein SUMOylation pathway are developed as potentially clinical anticancer therapeutics. Here, we systematically summarize the latest progresses of associations of small ubiquitin-like modifier (SUMO) enzymes with cancers and small-molecular inhibitors against human cancers by targeting SUMOylation enzymes. We also compared the pros and cons of several special anticancer inhibitors targeting SUMO pathway. As more efforts are invested in this field, small-molecule inhibitors targeting the SUMOylation modification pathway are promising for development into novel anticancer drugs.

Design, synthesis, and biological evaluation of benzodiazepine-based SUMO-specific protease 1 inhibitors.

Identification of SENP1 Inhibitors Through in Silico Screening and Rational Drug Design.

Benzothiophene-2-carboxamide derivatives as SENPs inhibitors with selectivity within SENPs family

Synthesis and Neuroprotective Biological Evaluation of Quinazolinone Derivatives Via Scaffold Hopping.

2-(4-Chlorophenyl)-2-oxoethyl 4-Benzamidobenzoate Derivatives, a Novel Class of SENP1 Inhibitors: Virtual Screening, Synthesis and Biological Evaluation.

Recent Research and Development of Inhibitors Targeting Sentrin-Specific Protease 1 for the Treatment of Cancers.

Design, Synthesis and Biological Evaluation of Novel Non-peptide Boronic Acid Derivatives As Proteasome Inhibitors

Design, Synthesis, and Biological Evaluation of Novel Phenol Ether Derivatives As Non-Covalent Proteasome Inhibitors.

Progress in the Discovery of Small Molecule Modulators of DeSUMOylation.

Design, Synthesis and Evaluation of 3-(2-aminoheterocycle)-4-benzyloxyphenylbenzamide Derivatives As BACE-1 Inhibitors

( S )- N -Benzyl-1-phenyl-3,4-dihydroisoqunoline-2(1 H )-carboxamide Derivatives, Multi-Target Inhibitors of Monoamine Oxidase and Cholinesterase: Design, Synthesis, and Biological Activity.

Design, Synthesis, Evaluation and 3D-QSAR Analysis of Benzosulfonamide Benzenesulfonates As Potent and Selective Inhibitors of MMP-2

Design, Synthesis, and Biological Evaluation of Potent EZH2/LSD1 Dual Inhibitors for Prostate Cancer

Development and Evaluation of a Highly Reliable Assay for SUMO-Specific Protease Inhibito R S

Design, Synthesis and Biological Activity of 3-Oxoamino-benzenesulfonamides As Selective and Reversible LSD1 Inhibitors.

Small-Molecule Inhibitors Targeting Protein SUMOylation As Novel Anticancer Compounds.

Research progression on biologic function and effect of SUMO-specific proteinase

Design, synthesis and biological evaluation of sulfamide and triazole benzodiazepines as novel p53-MDM2 inhibitors.

Design, Synthesis, and Biological Evaluation of Pyrido[2,3- d ]pyrimidin-7(8 H )-one Derivatives As Potent USP1 Inhibitors

Allosteric Inhibition of Ubiquitin-like Modifications by a Class of Inhibitor of SUMO-Activating Enzyme.

Design, Synthesis, and Biological Evaluation of 1-(Indolizin-3-yl)ethan-1-ones as CBP Bromodomain Inhibitors for the Treatment of Prostate Cancer